Research guide
Retatrutide: What the Research Actually Says
A plain-language, source-grounded look at the triple-agonist peptide LY3437943 — how it works, what trials measured, and how it compares to other studied compounds.
TL;DR
- • Retatrutide (LY3437943) is an investigational peptide that activates three receptors at once: GIP, GLP-1, and glucagon.
- • That third target — the glucagon receptor — is the main thing separating it from dual agonists like tirzepatide.
- • Its half-life is roughly six days, so published protocols dose it once weekly.
- • Phase 2 results published in 2023 reported dose-dependent weight and HbA1c changes over 24–48 weeks.
- • It is not FDA approved. Material from research suppliers is for in-vitro laboratory use only.
Key properties at a glance
- Compound nameRetatrutide (LY3437943)
- ClassTriple receptor agonist peptide
- TargetsGIP, GLP-1, glucagon receptors
- Reported half-life~6 days
- Study scheduleOnce weekly
- FormLyophilized powder, reconstituted before use
- StorageRefrigerated; protect from light and freeze-thaw
- Regulatory statusInvestigational — not approved
How Retatrutide works
Retatrutide is built to bind three different receptors that all help regulate how the body handles energy. Each receptor contributes something different in the published literature.
GLP-1 receptor
GLP-1 signaling is the most-studied of the three. In research models it slows gastric emptying and influences insulin release in a glucose-dependent way.
GIP receptor
GIP is a second incretin pathway. Studies of dual agonists suggest that adding GIP activity changes both insulin response and how adipose tissue handles nutrients.
Glucagon receptor
This is the differentiator. Glucagon receptor activity is studied for its role in energy expenditure and liver fat metabolism, which is why researchers group Retatrutide separately from GLP-1-only compounds.
Pharmacokinetics and study protocols
Published pharmacokinetic data describe a half-life near six days. That long exposure window is what makes once-weekly dosing feasible in trial designs.
Trials used stepwise dose escalation rather than starting at a target dose. Gradual titration was reported to reduce gastrointestinal adverse events during the first weeks.
- • Administration in studies: subcutaneous, once weekly
- • Escalation: low starting dose stepped up over several weeks
- • Trial durations reported: 24 weeks and 48 weeks
- • Most frequently reported adverse events: nausea, vomiting, diarrhea, usually during escalation
Retatrutide compared to other studied peptides
Comparison searches are common because these compounds sit on a spectrum of receptor coverage. The table below summarizes the mechanical differences only — not outcomes or recommendations.
| Compound | Receptor targets | Reported half-life |
|---|---|---|
| Retatrutide | GIP + GLP-1 + glucagon | ~6 days |
| Tirzepatide | GIP + GLP-1 | ~5 days |
| Semaglutide | GLP-1 only | ~7 days |
| Liraglutide | GLP-1 only | ~13 hours |
Retatrutide vs. tirzepatide
The single structural difference that matters most is glucagon receptor activity. Everything else about the two compounds — incretin coverage, weekly schedule, titration approach — is broadly similar in study design.
Retatrutide vs. semaglutide
Semaglutide acts on one receptor; Retatrutide acts on three. Researchers studying multi-receptor coverage often use semaglutide as the single-pathway reference point.
Handling in a research setting
Retatrutide ships as a lyophilized powder and is reconstituted with bacteriostatic water before use. Vial strength divided by water volume gives the working concentration.
Reconstituted material is light-sensitive and degrades with repeated freeze-thaw cycles. Refrigerated storage and single-direction handling preserve peptide integrity.
Frequently asked questions
This article is provided for laboratory research reference only. It is not medical advice, a treatment claim, or a dosing recommendation. Retatrutide is an investigational compound sold for in-vitro research use only.